Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. - Wikidata - awgldk - TriplyDB

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.

http://www.wikidata.org/entity/Q44408807

about

Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy KASL clinical practice guidelines: management of chronic hepatitis B Metabonomic window into hepatitis B virus-related hepatic diseases Recent advances in understanding and diagnosing hepatitis B virus infection Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Current hepatitis B treatment guidelines and future research directions.Chronic hepatitis B: Advances in treatment.Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.Baseline value of intrahepatic HBV DNA over cccDNA predicts patient's response to interferon therapy Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy?Hepatitis B virus genotypes and variants.Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis.Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B.Correlations of IFN-γ-inducible protein-10 with the risk of chronic hepatitis B and the efficacy of interferon therapy in Asians.Elimination of Hepatitis B: Is It a Mission Possible?CD3(bright)CD56(+) T cells associate with pegylated interferon-alpha treatment nonresponse in chronic hepatitis B patients.Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a Virus and Host Testing to Manage Chronic Hepatitis B.Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study.An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment.A rationalized approach to the treatment of patients infected with hepatitis B.HBsAg quantification: useful for monitoring natural history and treatment outcome.HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility.Peginterferon α in the treatment of chronic hepatitis B.Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China.Chronic hepatitis B virus in young adults: the need for new approaches to management.Re-appraisal of old and new diagnostic tools in the current management of chronic hepatitis B.Update on hepatitis B virus infection.HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?How to achieve immune control in chronic hepatitis B?Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance.Advances in therapeutics for chronic hepatitis B.Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.

P2860

Q26740161-84A9ACCA-502B-43AD-9708-D43640F2C745 Q26752475-B71955E4-1C34-4AE9-8817-DEBD83202EBD Q26771253-DFBF754C-5B08-456F-A39C-77ED66CA0299 Q28067419-3EF6F959-454F-4B9E-B0DE-94F43851BBEC Q30391932-DA9DA153-0CF7-4A79-8B07-5D53059B8BCD Q30487002-1AD16BF7-3403-40D0-976F-D9C8885D67C9 Q33660010-79746240-C0A3-43C9-8020-E3AEDAD88F24 Q33845546-5DD4EBD5-79C3-48B8-9A29-00390D9399F5 Q33918392-692F2A5A-D5AD-4268-A503-3252E14399C7 Q34785877-51D8EB73-774E-4082-8667-719BC83D8F23 Q35118955-8249A9DF-5097-4CED-9AE9-8D2FC961BC19 Q35663838-5830772D-E087-48FD-9465-B7409BC38D67 Q35688409-5630228D-0256-4425-8368-4E30A2A83137 Q35746110-B9AE907D-78DF-4DE4-9562-C82B98BA451D Q35866293-89439009-08B9-4FB1-9AF8-065582D69224 Q36014403-09CA502A-A9C3-4FFB-9E2E-2A172A4DDB4B Q36307834-3ABBC3E3-A622-4B96-BE03-DD4463B3E5EB Q36898390-B91E06AA-1153-4170-89F6-F6DEB23A6829 Q36924978-441FFD91-F243-410B-8814-C93B6006041E Q36958940-89468E74-A969-4916-BBE9-65396D88C6D2 Q37087279-5A579EE8-6623-4776-A0EC-834D8E4B7421 Q37165176-26D86616-5A35-4DCF-9560-331E7021204D Q37206545-2DFF5303-B62D-4804-9F57-5095750AA8D6 Q37482902-4D0194F2-AD1C-49DE-89C9-DA0664A0820C Q37684139-B5B2D54A-29EE-4DC9-8C89-0EF661CD1378 Q38168105-D89C53F2-5900-4EAC-BB0B-685737C3BCFD Q38174257-2BF45475-8268-4ECE-81A6-C8FA12E3387B Q38174259-3D94D23E-9815-45A7-BE86-A38CA9F738F5 Q38177851-F8374D4C-0B1D-4BA9-88A9-ACDC92A58AD4 Q38205028-9FC870C9-3A31-402C-BFAF-FE4815683F52 Q38210344-17F69F9E-3C5E-4FC0-9E64-2F3765856DCF Q38232829-B3A83D6C-90D3-4037-A173-53088F3BB6FD Q38237418-006BBFAF-03E8-4CA2-90D1-BDB7FD63F519 Q38259535-6CCF66FF-7680-40B2-8F46-47E51C2891EF Q38295840-537AC236-3E9D-4353-9EDC-F83DE1B11F57 Q38295850-BB016BFC-219C-4608-8391-7D7B1CD0EC4E Q38383489-0B727B80-D8E5-4FBB-AC44-186B3F8E4015 Q38408847-0B2E061B-5B31-48C8-B64F-981D930E73AA Q38585657-11E1A6CD-472A-4589-88F3-E58176FA59C7 Q38601876-813C39BA-70BB-40E2-A5E1-1757830E1426

P2860

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels.

http://www.wikidata.org/entity/Q44408807

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Response-guided peginterferon ...... itis B surface antigen levels.

@en

Response-guided peginterferon ...... itis B surface antigen levels.

@nl

type

label

Response-guided peginterferon ...... itis B surface antigen levels.

@en

Response-guided peginterferon ...... itis B surface antigen levels.

@nl

prefLabel

Response-guided peginterferon ...... itis B surface antigen levels.

@en

Response-guided peginterferon ...... itis B surface antigen levels.

@nl

P1433

Q44408807-990A5548-B0B3-4634-82F2-71FDCFDE8FAF

P1476

Q44408807-9FD9DFEE-5461-49E3-83CE-A338665715F9

P2093

Q44408807-1E9DB2B4-24A0-4AF6-BB84-A28B99ADC36D

Q44408807-356C948A-0201-4862-ACD3-CF5D8DC8445E

Q44408807-40098B61-3789-46E0-8D46-F4848AAA5B99

Q44408807-4C79FEC9-CF73-409A-AB26-6930AA989806

Q44408807-89D9677A-1FC9-46F2-9689-1D800E0AF178

Q44408807-BF9F0901-484D-4D59-9970-4B38341F3762

Q44408807-E34B08FA-73C4-4D41-9678-5B5E0265A4F5

Q44408807-FC859503-D63C-4C61-B19D-01F4D4FB0619

P2860

Q44408807-02CA0AD5-2769-4F6D-93A4-4123B1A9FD2C

Q44408807-0314659A-853F-4E6F-B686-F590C2660DBF

Q44408807-178A1B29-58C3-4FFB-BD29-432047E8F5F2

Q44408807-186998BD-806A-4815-8D2A-2D022F18DEC5

Q44408807-38A31D91-BFA5-475D-B3CC-D5C1A0A05FED

Q44408807-3DCB5902-93B2-4467-A0B9-20F31D7ED854

Q44408807-47198252-FCD0-4157-B6AB-7A4B495796D7

Q44408807-55F57DDF-A8FC-4D63-9BBD-04DC0557AFCB

Q44408807-5790A8CA-2DFB-4A7E-B0BB-60D46CEF73E2

Q44408807-5C4975AD-8325-4D3C-959E-8773E145C7B8

P304

Q44408807-B3262FF6-68D1-423F-914C-8E4D08E6C7C8

P31

Q44408807-948DD0B2-89C6-4FDA-A02E-9963C7BEA13E

P356

Q44408807-82A7794B-38E0-426E-B96F-90D5679A3254

P407

Q44408807-4729105B-3170-40EF-B052-0C54CD358FC4

P433

Q44408807-6DEDBCAC-4D35-4AF3-8B8F-503E76B3E411

P478

Q44408807-D0572A8C-2071-46E5-93B0-BF8C938C052A

P50

Q44408807-140839AC-586F-45B2-BA7F-64EFC0A21FAB

Q44408807-F3F316E9-883E-43EF-A7C1-E443BC59D337

Q44408807-b2618f0e-47d3-82d6-755b-907072707503

P577

Q44408807-B7527726-8F15-4A75-B64E-EA36A3E4DF5D

P698

Q44408807-DC32AC89-E585-4E82-8FCC-F9007BF4E87E

P356

P1433

P1476

Response-guided peginterferon ...... itis B surface antigen levels.

@en

P2093

E Jenny Heathcote

http://www.w3.org/2001/XMLSchema#string

Edward Gane

http://www.w3.org/2001/XMLSchema#string

Harry L A Janssen

http://www.w3.org/2001/XMLSchema#string

Henry L-Y Chan

http://www.w3.org/2001/XMLSchema#string

Ji-Dong Jia

http://www.w3.org/2001/XMLSchema#string

Milan J Sonneveld

http://www.w3.org/2001/XMLSchema#string

Qing Xie

http://www.w3.org/2001/XMLSchema#string

Teerha Piratvisuth

http://www.w3.org/2001/XMLSchema#string

P2860

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

Chronic hepatitis B: update 2009

Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B.

Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Hepatocellular carcinoma and hepatitis B virus.

Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.

Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.

P304

872-880

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.26436

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23553752

http://www.w3.org/2001/XMLSchema#string